Acknowledgments We thank ML Silverberg for assistance with development of nursing and postinfusion protocols. Screening Once identified as a candidate for chimeric antigen receptor (CAR) T-cell therapy, patients must undergo screening for eligibility. Prediagnostic evaluations are required to assess patient…
Introduction Chimeric antigen receptor (CAR) T-cells are one of the most rapidly growing cancer immunotherapies, particularly for B-cell malignancies. While the manufacturing of CAR T-cells is relatively straightforward, there are many barriers associated with the manufacturing process. Additionally, most CAR…
Conflicts of Interest The authors have no conflicts of interest to declare. The views expressed are the authors' own and do not represent the National Institutes of Health, the Department of Health and Human Services, or the US Federal government.…
Introduction Chimeric antigen receptor (CAR) T-cell immunotherapy is a rapidly emerging and highly publicized new treatment modality, which has gained significant attention for its effectiveness, side effects, and costs. Early-phase clinical trials have shown dramatic results in patients with often…